id,sentences,label,sentences_tokens,cuis
0,"62 ||| STATISTICAL ANALYSIS ||| 2.18 ||| Similar proportions of patients treated with oxytocin were successfully induced in both groups (P ¼.45); however, in subjects who did not receive oxytocin, significantly more (41 of 44, 93.2%) who were treated with misoprostol delivered vaginally within 24 hours compared with those treated with dinoprostone (21 of 34, 61.8%; P < .001).",I,proportions patients treated oxytocin induced 45 subjects receive oxytocin 41 44 93 2% treated misoprostol delivered vaginally 24 hours compared treated dinoprostone 21 34 61 8% < 001,C1709707|C0030705|C1522326|C0030095|C0205263|C0450371|C0681850|C1514756|C0030095|C0450371|C0450371|C0450371|G0000000|C1522326|C0085174|C1705822|G0000000|C0450371|C0439227|C1707455|C1522326|C0012472|C0450371|C0450371|C0450371|G0000000|G0000000|C1442061
1,99 ||| STATISTICAL ANALYSIS ||| 2.55 ||| Induction failure was defined as not entering into the active phase after 36 hours of misoprostol treatment with a maximal cumulative dosage of 1600 mg.,P,induction failure defined entering active phase 36 hours misoprostol treatment maximal cumulative dosage 1600,C0205263|C0231174|C1704788|C1522196|C0205177|C0205390|C0450371|C0439227|C0085174|C0039798|C0205289|C1511559|C0178602|G0000000
2,65 ||| STATISTICAL ANALYSIS ||| 2.21 ||| The small numbers preclude meaningful comparisons.,N,preclude meaningful comparisons,G0000000|C0876919|C1707455
3,41 ||| RESULTS ||| 1.4 ||| Approximately half had previous deliveries.,N,half previous deliveries,C2825407|C0205156|C0011209
4,36 |||  ||| 0.36 ||| Uterine tachysystole was defined as more than 5 contractions in a 10 minute period without fetal heart rate changes and uterine hyperstimulation as tachysystolic uterine contractions associated with nonreassuring fetal heart rate pattern.,N,uterine tachysystole defined 5 contractions 10 minute period fetal heart rate uterine hyperstimulation tachysystolic uterine contractions nonreassuring fetal heart rate pattern,C0042149|C2985339|C1704788|G0000000|C1140999|C0450371|C0439232|C0439531|C0015965|C0018787|C0871208|C0042149|G0000000|C2985339|C0042149|C1140999|G0000000|C0015965|C0018787|C0871208|C0449774
5,"106 ||| STATISTICAL ANALYSIS ||| 2.62 ||| Thaisomboon et al 12 compared hourly NICU admission, n (%) 0 6 (7.5) .028",I,thaisomboon al 12 compared hourly nicu admission % 0 6 7 5 028,G0000000|C0202311|C0450371|C1707455|C0558292|C0021709|C0184666|G0000000|G0000000|G0000000|G0000000|G0000000|C1442061
6,"30 |||  ||| 0.30 ||| If contractions subsequently became inadequate, oxytocin augmentation was provided at least 2 hours after the last misoprostol dose.",I,contractions subsequently inadequate oxytocin augmentation provided 2 hours misoprostol dose,C1140999|G0000000|C0205412|C0030095|C1293122|C1999230|G0000000|C0439227|C0085174|C0178602
7,16 |||  ||| 0.16 ||| Am J Obstet Gynecol 2014;210:56.e1-6.,P,obstet gynecol 2014 210 56 e1-6,G0000000|G0000000|G0000000|C1442061|C0450371|C1704625
8,"89 ||| STATISTICAL ANALYSIS ||| 2.45 ||| Cheng et al, 6 in 2008, reported that vaginal delivery within 24 hours was achieved in 94.1% of 101 women randomized to hourly titrated oral misoprostol, compared with 53.8% of 106 women treated with vaginal misoprostol (P < .01).",I,cheng al 6 2008 reported vaginal delivery 24 hours achieved 94 1% 101 women randomized hourly titrated oral misoprostol compared 53 8% 106 women treated vaginal misoprostol < 01,G0000000|C0202311|G0000000|G0000000|C0684224|C0042232|C0011209|C0450371|C0439227|G0000000|C0450371|G0000000|C1442061|C0043210|C0034656|C0558292|C1883350|C0442027|C0085174|C1707455|C0450371|G0000000|C1442061|C0043210|C1522326|C0042232|C0085174|G0000000|C0450371
9,"98 ||| STATISTICAL ANALYSIS ||| 2.54 ||| There was no statistical significant difference between the 2 groups in the proportion of vaginal deliveries within 24 hours (56% in the misoprostol group and 62% in the dinoprostone group; RR, 0.90, 95% CI, 0.72e1.14).",I,statistical difference 2 proportion vaginal deliveries 24 hours 56% misoprostol 62% dinoprostone rr 0 90 95% ci 0 72e1 14,C0038215|C1705241|G0000000|C1709707|C0042232|C0011209|C0450371|C0439227|C0450371|C0085174|C0450371|C0012472|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|G0000000|C0450371
10,"22 |||  ||| 0.22 ||| All women admitted to the KAUH (Jeddah, Saudi Arabia) for whom induction of labor was indicated by their attending obstetrician, who met the eligibility criteria, and from whom written informed consent was obtained by the physician were enrolled.",P,women admitted kauh jeddah saudi arabia induction labor attending obstetrician met eligibility criteria written informed consent physician enrolled,C0043210|C0184666|G0000000|G0000000|G0000000|C0003671|C0205263|C0022864|C1547429|C0334897|C0268621|C0013893|C0243161|C0043266|C1522154|C1511481|C0031831|G0000000
11,114 ||| STATISTICAL ANALYSIS ||| 2.70 ||| Our 45% oxytocin augmentation rate in the oral misoprostol group is within reported ranges.,I,45% oxytocin augmentation rate oral misoprostol reported ranges,C0450371|C0030095|C1293122|C0871208|C0442027|C0085174|C0684224|C1514721
12,"75 ||| STATISTICAL ANALYSIS ||| 2.31 ||| No neonates from the dinoprostone group had neonatal intensive care unit (NICU) admission, compared with 6 from the misoprostol group (7.5%; P ¼ .028).",I,neonates dinoprostone neonatal intensive care unit nicu admission compared 6 misoprostol 7 5% 028,C0021289|C0012472|C1552240|C0162425|C1947933|C0439148|C0021709|C0184666|C1707455|G0000000|C0085174|G0000000|G0000000|C1442061
13,101 ||| STATISTICAL ANALYSIS ||| 2.57 ||| This might have contributed to our lesser proportion of vaginal deliveries within 24 hours compared with those studies by Cheng et al.,O,contributed lesser proportion vaginal deliveries 24 hours compared studies cheng al,C1880177|C0547044|C1709707|C0042232|C0011209|C0450371|C0439227|C1707455|C0947630|G0000000|C0202311
14,"125 ||| STATISTICAL ANALYSIS ||| 2.81 ||| In conclusion, despite the small sample size, our labor induction with hourly titrated oral misoprostol approached statistical significance, supporting the potential use of hourly titrated oral misoprostol for labor induction.",O,conclusion sample size labor induction hourly titrated oral misoprostol approached statistical significance supporting potential hourly titrated oral misoprostol labor induction,C1707478|C0370003|C0456389|C0022864|C0205263|C0558292|C1883350|C0442027|C0085174|C0449445|C0038215|C0237881|C0183683|C3245505|C0558292|C1883350|C0442027|C0085174|C0022864|C0205263
15,127 ||| STATISTICAL ANALYSIS ||| 2.83 ||| 2,N,2,G0000000
16,7 |||  ||| 0.7 ||| Safety assessments included the incidence of maternal morbidity and adverse neonatal outcomes.,N,safety assessments included incidence maternal morbidity adverse neonatal outcomes,C0036043|C1261322|C0332257|C0021149|C2347083|C0026538|G0000000|C1552240|C1274040
17,"115 ||| STATISTICAL ANALYSIS ||| 2.71 ||| In one study, a 74.7% 24 hour vaginal delivery rate was achieved when 50 mg oral misoprostol was followed by up to 3 100 mg doses every more frequently in the misoprostol group, the rates of these and other maternal outcomes were not significantly different between groups.",O,study 74 7% 24 hour vaginal delivery rate achieved 50 oral misoprostol 3 100 doses frequently misoprostol rates maternal outcomes,C0557651|C0450371|G0000000|C0450371|C0439227|C0042232|C0011209|C0871208|G0000000|C0450371|C0442027|C0085174|G0000000|C1442061|C0178602|C0332183|C0085174|C0871208|C2347083|C1274040
18,"18 |||  ||| 0.18 ||| It reaches peak serum concentration in 30 minutes, followed by a rapid decline to low levels by 120 minutes, with a more gradual decline thereafter.",O,reaches peak serum concentration 30 minutes rapid decline low levels 120 minutes gradual decline,C0596012|C0444505|C0229671|C0004268|C0450371|C0439232|C0456962|G0000000|C0205251|C0441889|C1442061|C0439232|C0439833|G0000000
19,"9 |||  ||| 0.9 ||| Significantly more women with baseline Bishop score of 3 or less in the misoprostol group had successful induction (43 of 59, 72.9%) compared with the dinoprostone group (27 of 60, 45.0%; P ¼ .002).",I,women baseline bishop score 3 misoprostol successful induction 43 59 72 9% compared dinoprostone 27 60 45 0% 002,C0043210|C0168634|C1551458|C0449820|G0000000|C0085174|C0597535|C0205263|C0450371|C0450371|C0450371|G0000000|C1707455|C0012472|C0450371|C0450371|C0450371|G0000000|C1442061
20,77 ||| STATISTICAL ANALYSIS ||| 2.33 ||| The 6 infants were discharged home in good condition.,N,6 infants discharged condition,G0000000|C0021270|C0030685|C0012634
21,"31 |||  ||| 0.31 ||| Dinoprostone 10 mg vaginal insert (Propess; Controlled Therapeutics, East Kilbride, Scotland) was placed manually in the posterior fornix for a maximum of 24 hours or until the establishment of regular uterine activity and then was removed.",I,dinoprostone 10 vaginal insert propess controlled therapeutics east kilbride scotland manually posterior fornix maximum 24 hours establishment regular uterine activity removed,C0012472|C0450371|C0042232|C0441587|G0000000|C2587213|C0087111|C1707877|G0000000|C0036453|C3842330|C0205095|C0152334|C0806909|C0450371|C0439227|G0000000|C0205272|C0042149|C0205177|C0849355
22,"93 ||| STATISTICAL ANALYSIS ||| 2.49 ||| If contractions subsequently became inadequate, hourly doses of misoprostol solution were staradequate uterine contractions were achieved.",I,contractions subsequently inadequate hourly doses misoprostol solution staradequate uterine contractions achieved,C1140999|G0000000|C0205412|C0558292|C0178602|C0085174|C0037633|G0000000|C0042149|C1140999|G0000000
23,111 ||| STATISTICAL ANALYSIS ||| 2.67 ||| hourly for a maximum of 8 hours) with 56.e5 American Journal of Obstetrics & Gynecology JANUARY 2014 www.AJOG.org,I,hourly maximum 8 hours 56 e5 american journal obstetrics gynecology january 2014 ajog org,C0558292|C0806909|G0000000|C0439227|C0450371|C1704625|C0596070|C0162443|C0028773|C0018417|C3829466|G0000000|G0000000|C1522486
24,"104 ||| STATISTICAL ANALYSIS ||| 2.60 ||| 6,11",N,6 11,G0000000|C0450371
25,55 ||| STATISTICAL ANALYSIS ||| 2.11 ||| Proportions with vaginal delivery within 12 hours and interval from first treatment to vaginal delivery were not significantly different between groups.,I,proportions vaginal delivery 12 hours interval treatment vaginal delivery,C1709707|C0042232|C0011209|C0450371|C0439227|C1272706|C0039798|C0042232|C0011209
26,105 ||| STATISTICAL ANALYSIS ||| 2.61 ||| Apgar score <7 at 5 min 0 0 1.00,I,apgar score <7 5 min 0 0 1 00,C0741195|C0449820|G0000000|G0000000|C0702093|G0000000|G0000000|G0000000|C0450371
27,"26 |||  ||| 0.26 ||| Labor management at the KAUH is standardized and includes electronic fetal monitoring performed 1 hour before and 1 hour after the start of induction, which is continued after the beginning of uterine contractions until delivery.",I,labor management kauh standardized includes electronic fetal monitoring performed 1 hour 1 hour start induction continued uterine contractions delivery,C0022864|C0001554|G0000000|G0000000|C0332257|C0013850|C0015965|C0150369|C0884358|G0000000|C0439227|G0000000|C0439227|C0439659|C0205263|C0549178|C0042149|C1140999|C0011209
28,100 ||| STATISTICAL ANALYSIS ||| 2.56 ||| These researchers continue to report high success rates with hourly titrated oral misoprostol.,O,researchers continue report success rates hourly titrated oral misoprostol,C0035173|C0549178|C0684224|C0597535|C0871208|C0558292|C1883350|C0442027|C0085174
29,66 ||| STATISTICAL ANALYSIS ||| 2.22 ||| Frequencies of maternal adverse events were similar between groups (Table 3).,N,frequencies maternal adverse events table 3,C0439603|C2347083|G0000000|C0441471|C0039224|G0000000
30,71 ||| STATISTICAL ANALYSIS ||| 2.27 ||| There was one perinatal death in each group; both women were undergoing induction because of congenital anomalies.,N,perinatal death women undergoing induction congenital anomalies,C0178795|C0011065|C0043210|G0000000|C0205263|C0009678|C0000769
31,13 |||  ||| 0.13 ||| Vaginal delivery was CONCLUSION: Hourly titrated oral misoprostol can provide an effica-cious and safe substitute for the expensive dinoprostone vaginal insert.,O,vaginal delivery conclusion hourly titrated oral misoprostol provide effica-cious safe substitute expensive dinoprostone vaginal insert,C0042232|C0011209|C1707478|C0558292|C1883350|C0442027|C0085174|C1999230|G0000000|G0000000|G0000000|C0680864|C0012472|C0042232|C0441587
32,"28 |||  ||| 0.28 ||| Delivery is conducted by in-house staff, usually residents and senior residents under the care of the on-call consultant.",I,delivery conducted in-house staff residents senior residents care on-call consultant,C0011209|C0004927|C0150312|C0851286|C1320928|C1705825|C1320928|C1947933|C1720176|C0009817
33,"86 ||| STATISTICAL ANALYSIS ||| 2.42 ||| The median dosage of misoprostol used was 150 mg (range, 50e400 mg).",N,median dosage misoprostol 150 range 50e400,C0549183|C0178602|C0085174|C1442061|C1514721|G0000000
34,3 |||  ||| 0.3 ||| Misoprostol was given as 20 mg hourly for 2 doses.,I,misoprostol 20 hourly 2 doses,C0085174|C0450371|C0558292|G0000000|C0178602
35,84 ||| STATISTICAL ANALYSIS ||| 2.40 ||| Hourly titrated oral misoprostol.,I,hourly titrated oral misoprostol,C0558292|C1883350|C0442027|C0085174
36,"117 ||| STATISTICAL ANALYSIS ||| 2.73 ||| NICU admission rates ranging from 0% to 12% have been reported following labor induction with oral misoprostol 16,10,12 and 0.5% to 12% following vaginal dinoprostone induction.",I,nicu admission rates ranging 0% 12% reported labor induction oral misoprostol 16 10 12 0 5% 12% vaginal dinoprostone induction,C0021709|C0184666|C0871208|C1514721|G0000000|C0450371|C0684224|C0022864|C0205263|C0442027|C0085174|C0450371|C0450371|C0450371|G0000000|G0000000|C0450371|C0042232|C0012472|C0205263
37,"118 ||| STATISTICAL ANALYSIS ||| 2.74 ||| In one study, when dinoprostone was compared with oral and vaginal misoprostol, significantly different uterine hyperstimulation rates occurred (8.9%, 16.5%, and 21.4%; P ¼ .004).",I,study dinoprostone compared oral vaginal misoprostol uterine hyperstimulation rates occurred 8 9% 16 5% 21 4% 004,C0557651|C0012472|C1707455|C0442027|C0042232|C0085174|C0042149|G0000000|C0871208|C1709305|G0000000|G0000000|C0450371|G0000000|C0450371|G0000000|C1442061
38,37 |||  ||| 0.37 ||| Nonreassuring fetal heart rate was defined as an abnormal fetal heart rate on electronic monitoring.,P,nonreassuring fetal heart rate defined abnormal fetal heart rate electronic monitoring,G0000000|C0015965|C0018787|C0871208|C1704788|C0205161|C0015965|C0018787|C0871208|C0013850|C0150369
39,128 ||| STATISTICAL ANALYSIS ||| 2.84 ||| 1,N,1,G0000000
40,"48 ||| STATISTICAL ANALYSIS ||| 2.4 ||| In the absence of regular uterine activity, the dose was increased to 30 mg hourly for 3 doses and then 40 mg for 1 dose, 50 mg for 1 dose, and 60 mg hourly for 4 doses.",I,absence regular uterine activity dose increased 30 hourly 3 doses 40 1 dose 50 1 dose 60 hourly 4 doses,C0332197|C0205272|C0042149|C0205177|C0178602|C0205217|C0450371|C0558292|G0000000|C0178602|C0450371|G0000000|C0178602|C0450371|G0000000|C0178602|C0450371|C0558292|G0000000|C0178602
41,"51 ||| STATISTICAL ANALYSIS ||| 2.7 ||| At any time, if establishment of In the study by Cheng et al, 6 however, 94% of subjects delivered within 24 hours after oral titrated misoprostol, compared with 54% after vaginal misoprostol.",I,time establishment study cheng al 6 94% subjects delivered 24 hours oral titrated misoprostol compared 54% vaginal misoprostol,C0040223|G0000000|C0557651|G0000000|C0202311|G0000000|C0450371|C0681850|C1705822|C0450371|C0439227|C0442027|C1883350|C0085174|C1707455|C0450371|C0042232|C0085174
42,60 ||| STATISTICAL ANALYSIS ||| 2.16 ||| This was reflected by a significantly lower success rate within the dinoprostone group subjects who had low (45.0%) compared with high (85.0%) Bishop scores at baseline (P ¼ .002).,O,reflected lower success rate dinoprostone subjects low 45 0% compared 85 0% bishop scores baseline 002,C0558058|C0441994|C0597535|C0871208|C0012472|C0681850|C0205251|C0450371|G0000000|C1707455|C0450371|G0000000|C1551458|C0449820|C0168634|C1442061
43,10 |||  ||| 0.10 ||| Frequencies of maternal adverse events were similar between groups.,N,frequencies maternal adverse events,C0439603|C2347083|G0000000|C0441471
44,"59 ||| STATISTICAL ANALYSIS ||| 2.15 ||| Although the induction success was similar in misoprostol group women with baseline Bishop scores of 3 or less compared with 4-5 (P ¼ .346), significantly more women with a baseline Bishop score of 3 or less in the misoprostol group had successful induction (43 of 59, 72.9%) compared with women with low scores in the dinoprostone group (27 of 60, 45.0%; P ¼ .002).",P,induction success misoprostol women baseline bishop scores 3 compared 4-5 346 women baseline bishop score 3 misoprostol successful induction 43 59 72 9% compared women low scores dinoprostone 27 60 45 0% 002,C0205263|C0597535|C0085174|C0043210|C0168634|C1551458|C0449820|G0000000|C1707455|G0000000|C1442061|C0043210|C0168634|C1551458|C0449820|G0000000|C0085174|C0597535|C0205263|C0450371|C0450371|C0450371|G0000000|C1707455|C0043210|C0205251|C0449820|C0012472|C0450371|C0450371|C0450371|G0000000|C1442061
45,53 ||| STATISTICAL ANALYSIS ||| 2.9 ||| Analysis was performed on an intent-totreat basis.,N,analysis performed intent-totreat basis,C0002778|C0884358|C0162425|C1527178
46,83 ||| STATISTICAL ANALYSIS ||| 2.39 ||| Rouzi.,N,rouzi,G0000000
47,"94 ||| STATISTICAL ANALYSIS ||| 2.50 ||| No statistically significant differences were seen in the vaginal delivery within 24 hours (OMS: 62%, vaginal dinoprostone: 64%).",O,statistically differences vaginal delivery 24 hours oms 62% vaginal dinoprostone 64%,C0038215|C1705241|C0042232|C0011209|C0450371|C0439227|C1833692|C0450371|C0042232|C0012472|C0450371
48,"119 ||| STATISTICAL ANALYSIS ||| 2.75 ||| In a large study that enrolled 741 subjects, incidence of uterine hyperstimulation was 1.9% and 6.1% in the oral misoprostol and vaginal dinoprostone groups 16 and was 9% and 14% of 100 subjects in another study.",I,study enrolled 741 subjects incidence uterine hyperstimulation 1 9% 6 1% oral misoprostol vaginal dinoprostone 16 9% 14% 100 subjects study,C0557651|G0000000|C1442061|C0681850|C0021149|C0042149|G0000000|G0000000|G0000000|G0000000|G0000000|C0442027|C0085174|C0042232|C0012472|C0450371|G0000000|C0450371|C1442061|C0681850|C0557651
49,"29 |||  ||| 0.29 ||| Oral misoprostol was administered active labor was achieved, no further misoprostol was given.",N,oral misoprostol administered active labor achieved misoprostol,C0442027|C0085174|C1521801|C0205177|C0022864|G0000000|C0085174
50,"130 ||| ACKNOWLEDGMENT ||| 3.2 ||| The authors, therefore, acknowledge, with thanks, DSR technical and financial support.",I,authors acknowledge dsr technical financial support,C3812881|G0000000|C0596468|C0449851|C0376243|C0183683
51,"70 ||| STATISTICAL ANALYSIS ||| 2.26 ||| More infants in the dinoprostone group had a nonreassuring fetal heart rate (n ¼ 20, 25.0%) before delivery compared with the misoprostol group (n ¼ 10, 12.5%; P ¼ .043) ( Table 4).",I,infants dinoprostone nonreassuring fetal heart rate 20 25 0% delivery compared misoprostol 10 12 5% 043 table 4,C0021270|C0012472|G0000000|C0015965|C0018787|C0871208|C0450371|C0450371|G0000000|C0011209|C1707455|C0085174|C0450371|C0450371|G0000000|C1442061|C0039224|G0000000
52,"63 ||| STATISTICAL ANALYSIS ||| 2.19 ||| Cesarean delivery was performed in twice as many women in the dinoprostone (n ¼ 18) compared with the misoprostol group (n ¼ 9), approaching statistical significance (22.5% vs 11.3%; P ¼ .057).",I,cesarean delivery performed women dinoprostone 18 compared misoprostol 9 approaching statistical significance 22 5% 11 3% 057,C3841297|C0011209|C0884358|C0043210|C0012472|C0450371|C1707455|C0085174|G0000000|C0449445|C0038215|C0237881|C0450371|G0000000|C0450371|G0000000|C1442061
53,85 ||| STATISTICAL ANALYSIS ||| 2.41 ||| Am J Obstet Gynecol 2014.,N,obstet gynecol 2014,G0000000|G0000000|G0000000
54,"81 ||| STATISTICAL ANALYSIS ||| 2.37 ||| Study design and subject characteristic variations complicate outcome comparisons, and contribute to the motivation to perform additional studies in the specific settings in which safe and effective treatments will be applied.",O,study design subject characteristic variations complicate outcome comparisons contribute motivation perform additional studies specific settings safe effective treatments applied,C0557651|C1707689|C0681850|C1521970|C0205419|C0231242|C1274040|C1707455|C1880177|C0026605|C0884358|C1524062|C0947630|C0205369|C0542559|G0000000|C1280519|C0087111|C4048755
55,"4 |||  ||| 0.4 ||| In the absence of regular uterine contractions, the dose was increased to 30 mg hourly for 3 doses and then 40 mg for 1 dose, 50 mg for 1 dose, and 60 mg hourly for 4 doses.",I,absence regular uterine contractions dose increased 30 hourly 3 doses 40 1 dose 50 1 dose 60 hourly 4 doses,C0332197|C0205272|C0042149|C1140999|C0178602|C0205217|C0450371|C0558292|G0000000|C0178602|C0450371|G0000000|C0178602|C0450371|G0000000|C0178602|C0450371|C0558292|G0000000|C0178602
56,52 ||| STATISTICAL ANALYSIS ||| 2.8 ||| Using an intermediate projection of 60% delivery within 24 hours for dinoprostone and 80% for misoprostol would require 82 subjects per group at alpha ¼ .05 with 80% power.,I,intermediate projection 60% delivery 24 hours dinoprostone 80% misoprostol require 82 subjects alpha 05 80% power,C0205103|C0016538|C0450371|C0011209|C0450371|C0439227|C0012472|C0450371|C0085174|G0000000|C0450371|C0681850|C0439095|C0450371|C0450371|C0032863
57,"64 ||| STATISTICAL ANALYSIS ||| 2.20 ||| Cesarean deliveries were performed less than 24 hours after treatment in 7 subjects in the dinoprostone group (38.9%), compared with 6 in the misoprostol group (66.7%).",I,cesarean deliveries performed 24 hours treatment 7 subjects dinoprostone 38 9% compared 6 misoprostol 66 7%,C3841297|C0011209|C0884358|C0450371|C0439227|C0039798|G0000000|C0681850|C0012472|C0450371|G0000000|C1707455|G0000000|C0085174|C0450371|G0000000
58,110 ||| STATISTICAL ANALYSIS ||| 2.66 ||| Am J Obstet Gynecol 2014.,N,obstet gynecol 2014,G0000000|G0000000|G0000000
59,"73 ||| STATISTICAL ANALYSIS ||| 2.29 ||| A third subject with a fetus with congenital anomalies, also in the misoprostol group, underwent vaginal delivery approximately 29 hours after the start of induction.",I,subject fetus congenital anomalies misoprostol underwent vaginal delivery 29 hours start induction,C0681850|C0015965|C0009678|C0000769|C0085174|G0000000|C0042232|C0011209|C0450371|C0439227|C0439659|C0205263
60,"82 ||| STATISTICAL ANALYSIS ||| 2.38 ||| Hofmeyr et al, 7 in 2001, published a pilot study from South Africa on the use of the new protocol using oral 2 hour   Data are number (percentage).",N,hofmeyr al 7 2001 published pilot study south africa protocol oral 2 hour data percentage,G0000000|C0202311|G0000000|G0000000|C0034037|C0473169|C0557651|C1710133|C0001737|C0442711|C0442027|G0000000|C0439227|C1511726|C0439165
61,"97 ||| STATISTICAL ANALYSIS ||| 2.53 ||| The median misoprostol dose ted at 10 mg, which could be increased to 20 mg or 40 mg based on uterine was 240 mg (range, 40e475 mg).",I,median misoprostol dose ted 10 increased 20 40 based uterine 240 range 40e475,C0549183|C0085174|C0178602|C1539997|C0450371|C0205217|C0450371|C0450371|C1527178|C0042149|C1442061|C1514721|G0000000
62,6 |||  ||| 0.6 ||| The primary outcome variable was vaginal delivery within 24 hours.,O,primary outcome variable vaginal delivery 24 hours,C0205225|C1274040|C0439828|C0042232|C0011209|C0450371|C0439227
63,11 |||  ||| 0.11 ||| RESULTS: A total of 160 women was enrolled in the study.,P,total 160 women enrolled study,C0439175|C1442061|C0043210|G0000000|C0557651
64,35 |||  ||| 0.35 ||| Safety assessments included the incidence of maternal morbidity and adverse neonatal outcomes.,N,safety assessments included incidence maternal morbidity adverse neonatal outcomes,C0036043|C1261322|C0332257|C0021149|C2347083|C0026538|G0000000|C1552240|C1274040
65,123 ||| STATISTICAL ANALYSIS ||| 2.79 ||| Other limitations of our RCT include the small size.,N,limitations rct size,C0449295|G0000000|C0456389
66,"116 ||| STATISTICAL ANALYSIS ||| 2.72 ||| Similarly, other studies reported no difference in maternal side effects between oral misoprostol and vaginal dinoprostone treatment.",N,studies reported difference maternal effects oral misoprostol vaginal dinoprostone treatment,C0947630|C0684224|C1705241|C2347083|C1280500|C0442027|C0085174|C0042232|C0012472|C0039798
67,27 |||  ||| 0.27 ||| Intramuscular or intravenous analgesia is given for pain relief during labor.,O,intramuscular intravenous analgesia pain relief labor,C0021492|C0348016|C0002766|C0030193|C0564405|C0022864
68,"96 ||| STATISTICAL ANALYSIS ||| 2.52 ||| In 2003, the same research group from South Africa reported a 3 arm RCT comparing Foley's catheter and titrated misoprostol, titrated misoprostol, and tol (20 mg given every 2 hours for 2 doses and increased to 40 mg every 2 hours for a maximum of 10 doses) and vaginal dinoprostone (2 mg twice, 6 hours apart).",I,2003 south africa reported 3 arm rct comparing foleys catheter titrated misoprostol titrated misoprostol tol 20 2 hours 2 doses increased 40 2 hours maximum 10 doses vaginal dinoprostone 2 6 hours,G0000000|C1710133|C0001737|C0684224|G0000000|C0446516|G0000000|C1707455|G0000000|C0085590|C1883350|C0085174|C1883350|C0085174|G0000000|C0450371|G0000000|C0439227|G0000000|C0178602|C0205217|C0450371|G0000000|C0439227|C0806909|C0450371|C0178602|C0042232|C0012472|G0000000|G0000000|C0439227
69,90 ||| STATISTICAL ANALYSIS ||| 2.46 ||| The misoprostol protocol used 20 mg hourly for 4 doses and then 40 mg hourly for 4 doses and 60 mg 20 mg every 2 hours for 2 doses (Liverpool) or 3 doses (Johannesburg) and for OMS and vaginal dinoprostone were followed.,I,misoprostol protocol 20 hourly 4 doses 40 hourly 4 doses 60 20 2 hours 2 doses liverpool 3 doses johannesburg oms vaginal dinoprostone,C0085174|C0442711|C0450371|C0558292|G0000000|C0178602|C0450371|C0558292|G0000000|C0178602|C0450371|C0450371|G0000000|C0439227|G0000000|C0178602|G0000000|G0000000|C0178602|G0000000|C1833692|C0042232|C0012472
70,50 ||| STATISTICAL ANALYSIS ||| 2.6 ||| Regular uterine activity is defined as regular uterine contractions every 3-5 minutes and lasting 60 seconds or more.,I,regular uterine activity defined regular uterine contractions 3-5 minutes lasting 60,C0205272|C0042149|C0205177|C1704788|C0205272|C0042149|C1140999|G0000000|C0439232|C1517741|C0450371
71,"8 |||  ||| 0.8 ||| The proportion of women who achieved vaginal delivery within 24 hours was significantly greater for nulliparous women in the misoprostol group (24 of 51, 58.5%) compared with the dinoprostone group (12 of 36, 33.3%; P ¼ .0270).",I,proportion women achieved vaginal delivery 24 hours nulliparous women misoprostol 24 51 58 5% compared dinoprostone 12 36 33 3% 0270,C1709707|C0043210|G0000000|C0042232|C0011209|C0450371|C0439227|C0425979|C0043210|C0085174|C0450371|C0450371|C0450371|G0000000|C1707455|C0012472|C0450371|C0450371|C0450371|G0000000|G0000000
72,109 ||| STATISTICAL ANALYSIS ||| 2.65 ||| Hourly titrated oral misoprostol.,I,hourly titrated oral misoprostol,C0558292|C1883350|C0442027|C0085174
73,"32 |||  ||| 0.32 ||| If contractions subsequently became inadequate, oxytocin augmentation was provided at least half an hour after removal of the insert.",I,contractions subsequently inadequate oxytocin augmentation provided half hour removal insert,C1140999|G0000000|C0205412|C0030095|C1293122|C1999230|C2825407|C0439227|C0015252|C0441587
74,"5 |||  ||| 0.5 ||| Before the 40 and 50 mg doses, 1 more hour of observation was given.",I,40 50 doses 1 hour observation,C0450371|C0450371|C0178602|G0000000|C0439227|C0302523
75,78 ||| STATISTICAL ANALYSIS ||| 2.34 ||| COMMENT,N,comment,C0282411
76,23 |||  ||| 0.23 ||| Inclusion criteria included singleton pregnancy of at least 34 weeks' gestation and a baseline Bishop score less than 6.,P,inclusion criteria included singleton pregnancy 34 weeks gestation baseline bishop score 6,C0007637|C0243161|C0332257|C0481462|C0032961|C0450371|C0439230|C0032961|C0168634|C1551458|C0449820|G0000000
77,"46 ||| STATISTICAL ANALYSIS ||| 2.2 ||| Several studies comparing oral misoprostol with vaginal prostaglandins for the induction of labor failed to show a statistically significant difference in rates of vaginal delivery within 24 hours, with success rates ranging from 54% to 74%.",O,studies comparing oral misoprostol vaginal prostaglandins induction labor failed statistically difference rates vaginal delivery 24 hours success rates ranging 54% 74%,C0947630|C1707455|C0442027|C0085174|C0042232|C0033554|C0205263|C0022864|C0231175|C0038215|C1705241|C0871208|C0042232|C0011209|C0450371|C0439227|C0597535|C0871208|C1514721|C0450371|C0450371
78,"76 ||| STATISTICAL ANALYSIS ||| 2.32 ||| NICU admission was based on neonatal hypoglycemia because of maternal type 1 diabetes (n ¼ 3), growth restriction (n ¼ 2), and meconium aspiration (n ¼ 1).",P,nicu admission based neonatal hypoglycemia maternal type 1 diabetes 3 growth restriction 2 meconium aspiration 1,C0021709|C0184666|C1527178|C1552240|C0020615|C2347083|C0332307|G0000000|C0011847|G0000000|C0018270|C0443288|G0000000|C0025047|C0220787|G0000000
79,"68 ||| STATISTICAL ANALYSIS ||| 2.24 ||| Treatment was interrupted for 6.5 hours, during which time her condition stabilized.",I,treatment interrupted 6 5 hours time condition stabilized,C0039798|C0443239|G0000000|G0000000|C0439227|C0040223|C0012634|C0184512
80,"19 |||  ||| 0.19 ||| There are limited data, however, regarding the use of hourly titrated oral misoprostol.",I,limited data hourly titrated oral misoprostol,C0439801|C1511726|C0558292|C1883350|C0442027|C0085174
81,"121 ||| STATISTICAL ANALYSIS ||| 2.77 ||| Although these events occurred Women and clinicians were not blinded to the allocated treatment, which raises the possibility of bias in clinical management decisions.",I,events occurred women clinicians blinded allocated treatment raises possibility bias clinical management decisions,C0441471|C1709305|C0043210|C0871685|C0150108|G0000000|C0039798|G0000000|C0332149|C0242568|C0205210|C0001554|C0679006
82,"67 ||| STATISTICAL ANALYSIS ||| 2.23 ||| One woman in the misoprostol group experienced uterine tachysystole and hyperstimulation accompanied by shivering, vomiting, and nausea after 3 doses.",N,woman misoprostol experienced uterine tachysystole hyperstimulation accompanied shivering vomiting nausea 3 doses,C0043210|C0085174|C0237607|C0042149|C2985339|G0000000|G0000000|C0036973|C0042963|C0027497|G0000000|C0178602
83,2 |||  ||| 0.2 ||| STUDY DESIGN: Subjects were randomized into hourly titrated oral misoprostol or dinoprostone 10 mg vaginal insert.,I,study design subjects randomized hourly titrated oral misoprostol dinoprostone 10 vaginal insert,C0557651|C1707689|C0681850|C0034656|C0558292|C1883350|C0442027|C0085174|C0012472|C0450371|C0042232|C0441587
84,"34 |||  ||| 0.34 ||| Secondary outcomes included interval to delivery from first treatment (hours), rate of cesarean delivery, and need for augmentation with oxytocin.",I,secondary outcomes included interval delivery treatment hours rate cesarean delivery augmentation oxytocin,C0027627|C1274040|C0332257|C1272706|C0011209|C0039798|C0439227|C0871208|C3841297|C0011209|C1293122|C0030095
85,"80 ||| STATISTICAL ANALYSIS ||| 2.36 ||| ACOG states that ""no studies indicate that intrapartum exposure to misoprostol has any long-term adverse health consequences to the fetus in the absence of fetal distress, nor is there a plausible biologic basis for such a concern.""",N,acog studies intrapartum exposure misoprostol long-term adverse health consequences fetus absence fetal distress plausible biologic basis concern,C1515938|C0947630|C0456337|C0274281|C0085174|C0443252|G0000000|C0018684|C0686907|C0015965|C0332197|C0015965|C0231303|G0000000|C0005515|C1527178|C2699424
86,"87 ||| STATISTICAL ANALYSIS ||| 2.43 ||| Oral misoprostol solution was given as Within each study, similar delivery outcomes were achieved in each group.",O,oral misoprostol solution study delivery outcomes achieved,C0442027|C0085174|C0037633|C0557651|C0011209|C1274040|G0000000
87,69 ||| STATISTICAL ANALYSIS ||| 2.25 ||| At that time the subject was given dinoprostone and underwent an uneventful vaginal delivery of a 3540 g male infant after an additional 19 hours.,I,time subject dinoprostone underwent uneventful vaginal delivery 3540 male infant additional 19 hours,C0040223|C0681850|C0012472|G0000000|G0000000|C0042232|C0011209|G0000000|C0086582|C0021270|C1524062|C0450371|C0439227
88,102 ||| STATISTICAL ANALYSIS ||| 2.58 ||| Perinatal death 1 (1.25) 1 (1.25) 1.00,N,perinatal death 1 1 25 1 1 25 1 00,C0178795|C0011065|G0000000|G0000000|C0450371|G0000000|G0000000|C0450371|G0000000|C0450371
89,"91 ||| STATISTICAL ANALYSIS ||| 2.47 ||| The proportion of vaginal deliveries within 24 hours was similar in the 3 groups (55% in the Foley's catheter and misoprostol group, 60% in the misoprostol group, and 60% in the dinoprostone group).",I,proportion vaginal deliveries 24 hours 3 55% foleys catheter misoprostol 60% misoprostol 60% dinoprostone,C1709707|C0042232|C0011209|C0450371|C0439227|G0000000|C0450371|G0000000|C0085590|C0085174|C0450371|C0085174|C0450371|C0012472
90,40 ||| RESULTS ||| 1.3 ||| They were 28.8 AE 5.5 years of age.,P,28 8 ae 5 5 age,C0450371|G0000000|C3887670|G0000000|G0000000|C0001779
91,108 ||| STATISTICAL ANALYSIS ||| 2.64 ||| Rouzi.,N,rouzi,G0000000
92,95 ||| STATISTICAL ANALYSIS ||| 2.51 ||| The median and maximum doses of OMS used were not reported.,N,median maximum doses oms reported,C0549183|C0806909|C0178602|C1833692|C0684224
93,"88 ||| STATISTICAL ANALYSIS ||| 2.44 ||| Our success rate in the entire cohort was similar to what is reported in the literature (63%); however, the 15% difference between dinoprostone (55%) and misoprostol (70%) subjects bordered on statistical significance (P ¼ .05).",N,success rate entire cohort reported literature 63% 15% difference dinoprostone 55% misoprostol 70% subjects bordered statistical significance 05,C0597535|C0871208|C0439751|C0599755|C0684224|C0023866|C0450371|C0450371|C1705241|C0012472|C0450371|C0085174|C0450371|C0681850|C0205284|C0038215|C0237881|C0450371
94,"43 ||| RESULTS ||| 1.6 ||| Women in the misoprostol group received a median of 9 (range, 2e11) doses (median dose, 340 mg; range, 40e460 mg).",I,women misoprostol received median 9 range 2e11 doses median dose 340 range 40e460,C0043210|C0085174|C1514756|C0549183|G0000000|C1514721|G0000000|C0178602|C0549183|C0178602|C1442061|C1514721|G0000000
95,"61 ||| STATISTICAL ANALYSIS ||| 2.17 ||| Oxytocin was used in fewer patients in the misoprostol group (n ¼ 36, 45.0%) compared with the dinoprostone group (n ¼ 46, 57.5%); however, the difference was not statistically significant (P ¼ .114).",O,oxytocin fewer patients misoprostol 36 45 0% compared dinoprostone 46 57 5% difference statistically 114,C0030095|C0205388|C0030705|C0085174|C0450371|C0450371|G0000000|C1707455|C0012472|C0450371|C0450371|G0000000|C1705241|C0038215|C1442061
96,"56 ||| STATISTICAL ANALYSIS ||| 2.12 ||| Proportions achieving vaginal delivery within 24 hours were similar between groups for women with previous childbirth (P ¼ .313); however, the proportion of women successfully induced was significantly greater for nulliparous women in the misoprostol group (24 of 51, 58.5%) compared with the dinoprostone vaginal insert group (12 of 36, 33.3%; P ¼ .027).",I,proportions achieving vaginal delivery 24 hours women previous childbirth 313 proportion women induced nulliparous women misoprostol 24 51 58 5% compared dinoprostone vaginal insert 12 36 33 3% 027,C1709707|G0000000|C0042232|C0011209|C0450371|C0439227|C0043210|C0205156|C0005615|C1442061|C1709707|C0043210|C0205263|C0425979|C0043210|C0085174|C0450371|C0450371|C0450371|G0000000|C1707455|C0012472|C0042232|C0441587|C0450371|C0450371|C0450371|G0000000|C1442061
97,"124 ||| STATISTICAL ANALYSIS ||| 2.80 ||| In addition to limitations on the primary endpoint, the disadvantages of small studies are particularly evident when assessing safety, in which detecting a significant increase in adverse events that have a low background incidence can require an unachievable number of subjects.",N,addition limitations primary endpoint disadvantages studies evident assessing safety detecting increase adverse events low background incidence require unachievable subjects,C0332287|C0449295|C0205225|C2349179|G0000000|C0947630|C3887511|C1516048|C0036043|C0442726|C0442805|G0000000|C0441471|C0205251|C1706907|C0021149|G0000000|G0000000|C0681850
98,"42 ||| RESULTS ||| 1.5 ||| Three fourths of the women had a Bishop score of 3 or less at baseline, and postterm was the primary induction indication for 93 (58.1%) women.",P,fourths women bishop score 3 baseline postterm primary induction indication 93 58 1% women,C0205438|C0043210|C1551458|C0449820|G0000000|C0168634|C1398117|C0205225|C0205263|C0392360|C0450371|C0450371|G0000000|C0043210
99,"129 ||| ACKNOWLEDGMENT ||| 3.1 ||| This project was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant 5 / 11 /430.",N,project funded deanship scientific dsr king abdulaziz university jeddah grant 5 / 11 /430,C1709701|C0016820|G0000000|C0036397|C0596468|G0000000|G0000000|C0041740|G0000000|C0018173|G0000000|G0000000|C0450371|C1442061
100,"49 ||| STATISTICAL ANALYSIS ||| 2.5 ||| Before administering the 40 mg and 50 mg doses, 1 more hour of observation was given.",I,administering 40 50 doses 1 hour observation,C1533734|C0450371|C0450371|C0178602|G0000000|C0439227|C0302523
101,"92 ||| STATISTICAL ANALYSIS ||| 2.48 ||| In 2003, Dällenbach et al 10 published an RCT between titrated oral misoprosincreased to 40 mg every 2 hours until hourly until adequate uterine contractions occurred.",I,2003 dllenbach al 10 published rct titrated oral misoprosincreased 40 2 hours hourly adequate uterine contractions occurred,G0000000|G0000000|C0202311|C0450371|C0034037|G0000000|C1883350|C0442027|G0000000|C0450371|G0000000|C0439227|C0558292|C0205410|C0042149|C1140999|C1709305
102,"113 ||| STATISTICAL ANALYSIS ||| 2.69 ||| The 24 hour delivery rate was 28.1% and 46.9% in the titrated and static dose groups, respectively, despite a significantly higher mean total misoprostol dose given subjects in the titrated group (236.2 vs 103.1 mg; P ¼ .001).",I,24 hour delivery rate 28 1% 46 9% titrated static dose total misoprostol dose subjects titrated 236 2 103 1 001,C0450371|C0439227|C0011209|C0871208|C0450371|G0000000|C0450371|G0000000|C1883350|C0441463|C0178602|C0439175|C0085174|C0178602|C0681850|C1883350|C1442061|G0000000|C1442061|G0000000|C1442061
103,"33 |||  ||| 0.33 ||| The primary outcome variable was successful labor induction, defined as the proportion of women achieving vaginal delivery within 24 hours after treatment initiation.",O,primary outcome variable successful labor induction defined proportion women achieving vaginal delivery 24 hours treatment initiation,C0205225|C1274040|C0439828|C0597535|C0022864|C0205263|C1704788|C1709707|C0043210|G0000000|C0042232|C0011209|C0450371|C0439227|C0039798|C0589507
104,21 |||  ||| 0.21 ||| The objective of this study was to compare the efficacy and safety of a stepwise protocol of hourly titrated oral misoprostol with vaginal dinoprostone insert in women scheduled for labor induction.,P,objective study compare efficacy safety stepwise protocol hourly titrated oral misoprostol vaginal dinoprostone insert women scheduled labor induction,C0018017|C0557651|C1707455|C1280519|C0036043|G0000000|C0442711|C0558292|C1883350|C0442027|C0085174|C0042232|C0012472|C0441587|C0043210|C0086960|C0022864|C0205263
105,"54 ||| STATISTICAL ANALYSIS ||| 2.10 ||| Dichotomous variables were compared between groups using c 2 analysis, and continuous variables using delivery was achieved within 24 hours in 100 subjects (62.5%): 44 (42 normal vaginal deliveries and 2 ventouse extractions) in the dinoprostone vaginal insert group (55.0%) and 56 (55 normal vaginal deliveries and 1 ventouse extraction) in the misoprostol group (70.0%) (P ¼ .05; power, 50%; relative risk relative risk [RR], 1.5, 95% confidence interval [CI], 0.99e2.27) ( Table 2).",I,dichotomous variables compared 2 analysis continuous variables delivery achieved 24 hours 100 subjects 62 5% 44 42 normal vaginal deliveries 2 ventouse extractions dinoprostone vaginal insert 55 0% 56 55 normal vaginal deliveries 1 ventouse extraction misoprostol 70 0% 05 power 50% relative risk relative risk rr 1 5 95% confidence interval ci 0 99e2 27 table 2,C2827654|C0439828|C1707455|G0000000|C0002778|C0549178|C0439828|C0011209|G0000000|C0450371|C0439227|C1442061|C0681850|C0450371|G0000000|C0450371|C0450371|C0205307|C0042232|C0011209|G0000000|G0000000|C0185115|C0012472|C0042232|C0441587|C0450371|G0000000|C0450371|C0450371|C0205307|C0042232|C0011209|G0000000|G0000000|C0185115|C0085174|C0450371|G0000000|C0450371|C0032863|C0450371|C0080103|C0035647|C0080103|C0035647|G0000000|G0000000|G0000000|C0450371|C0237529|C1272706|C0008107|G0000000|G0000000|C0450371|C0039224|G0000000
106,47 ||| STATISTICAL ANALYSIS ||| 2.3 ||| The starting dose was 20 mg hourly for 2 doses.,I,starting dose 20 hourly 2 doses,C0439659|C0178602|C0450371|C0558292|G0000000|C0178602
107,"122 ||| STATISTICAL ANALYSIS ||| 2.78 ||| However, such an effect can operate in either direction and is minimized by our standard labor ward management policies.",N,operate direction minimized standard labor ward management policies,C3242339|C0449738|G0000000|C1442989|C0022864|C1305702|C0001554|C0242456
108,39 ||| RESULTS ||| 1.2 ||| The groups were similar for demographic and clinical factors (Table 1).,N,demographic clinical factors table 1,C0011298|C0205210|C1521761|C0039224|G0000000
109,"57 ||| STATISTICAL ANALYSIS ||| 2.13 ||| In addition, proportions were similar between groups for women with indications for induction other than status postterm, whereas significantly more misoprostol-treated postterm women delivered vaginally within 24 hours (37 of 48, 77.1%) compared with dinoprostonetreated women (25 of 45, 55.6%; P ¼ .028).",P,addition proportions women indications induction status postterm misoprostol-treated postterm women delivered vaginally 24 hours 37 48 77 1% compared dinoprostonetreated women 25 45 55 6% 028,C0332287|C1709707|C0043210|C0392360|C0205263|C0449438|C1398117|C0085174|C1398117|C0043210|C1705822|G0000000|C0450371|C0439227|C0450371|C0450371|C0450371|G0000000|C1707455|G0000000|C0043210|C0450371|C0450371|C0450371|G0000000|C1442061
110,"25 |||  ||| 0.25 ||| Women were randomized into the misoprostol or dinoprostone groups (1:1) using computer-generated numbers, with allocation concealed in opaque envelopes distributed by the obstetrics ward nurse.",N,women randomized misoprostol dinoprostone 1 1 computer-generated allocation concealed opaque envelopes distributed obstetrics ward nurse,C0043210|C0034656|C0085174|C0012472|G0000000|G0000000|C0009622|C1706778|C0443189|C0029053|C1622204|C1704711|C0028773|C1305702|C0028661
111,1 |||  ||| 0.1 ||| OBJECTIVE: The objective of the study was to compare the efficacy and safety of hourly titrated oral misoprostol with vaginal dinoprostone insert.,P,objective objective study compare efficacy safety hourly titrated oral misoprostol vaginal dinoprostone insert,C0018017|C0018017|C0557651|C1707455|C1280519|C0036043|C0558292|C1883350|C0442027|C0085174|C0042232|C0012472|C0441587
112,"38 ||| RESULTS ||| 1.1 ||| A total of 160 women were enrolled between January 2011 and July 2012, of whom 80 were randomized to the misoprostol and 80 to the dinoprostone vaginal insert groups (Figure).",P,total 160 women enrolled january 2011 july 2012 80 randomized misoprostol 80 dinoprostone vaginal insert figure,C0439175|C1442061|C0043210|G0000000|C3829466|G0000000|C3829447|G0000000|C0450371|C0034656|C0085174|C0450371|C0012472|C0042232|C0441587|G0000000
113,"45 ||| STATISTICAL ANALYSIS ||| 2.1 ||| Pharmaceuticals, Leicester, UK) dissolved in 200 mL of water, following the procedure described in other studies.",I,pharmaceuticals leicester uk dissolved 200 water procedure studies,C1135440|G0000000|C0041700|C1549535|C1442061|C0043047|C0184661|C0947630
114,112 ||| STATISTICAL ANALYSIS ||| 2.68 ||| Obstetrics Research static dosing (50 mg of misoprostol orally every 4 hours up to 12 hours) in a small study (32 women/group) reported in 2012.,I,obstetrics static dosing 50 misoprostol orally 4 hours 12 hours study 32 women/group reported 2012,C0028773|C0441463|G0000000|C0450371|C0085174|C0442027|G0000000|C0439227|C0450371|C0439227|C0557651|C0450371|C0242543|C0684224|G0000000
115,"24 |||  ||| 0.24 ||| Women with contraindications for use of either drug, previous cesarean section or other uterine surgery, severe pregnancy-induced hypertension (abnormal liver function tests, protein >1 g/d, blood pressure of !160/ 100 mm Hg), parity of 4 or more, or with uterine contractions were excluded.",P,women contraindications drug previous cesarean uterine surgery severe pregnancy-induced hypertension abnormal liver function tests protein 1 g/d blood pressure 160/ 100 mm hg parity 4 uterine contractions excluded,C0043210|C0079164|C0013227|C0205156|C3841297|C0042149|C0038894|C0205082|C0032961|C0020538|C0205161|C0023884|C0031843|C0022885|C0033684|G0000000|C0439417|C0005767|C0033095|C1442061|C1442061|G0000000|C0025424|C0030563|G0000000|C0042149|C1140999|C1554077
116,"44 ||| RESULTS ||| 1.7 ||| In the entire cohort, vaginal from a 1 mg/mL solution prepared from a 200 mg misoprostol tablet (Cytotec; Searle",I,entire cohort vaginal 1 mg/ml solution prepared 200 misoprostol tablet cytotec searle,C0439751|C0599755|C0042232|G0000000|C0439294|C0037633|C4082130|C1442061|C0085174|C0039225|C0591321|C0331897
117,"107 ||| STATISTICAL ANALYSIS ||| 2.63 ||| titrated misoprostol dosing (20 mg hourly orally for 4 doses and then 40 mg NICU, neonatal intensive care unit.",I,titrated misoprostol dosing 20 hourly orally 4 doses 40 nicu neonatal intensive care unit,C1883350|C0085174|G0000000|C0450371|C0558292|C0442027|G0000000|C0178602|C0450371|C0021709|C1552240|C0162425|C1947933|C0439148
118,"120 ||| STATISTICAL ANALYSIS ||| 2.76 ||| An adverse reaction considered related to misoprostol resulted in switching 1 subject in our study to dinoprostone because of uterine tachysystole and hyperstimulation, shivering, vomiting, and nausea.",N,adverse reaction considered misoprostol switching 1 subject study dinoprostone uterine tachysystole hyperstimulation shivering vomiting nausea,G0000000|C0443286|C0750591|C0085174|C1707719|G0000000|C0681850|C0557651|C0012472|C0042149|C2985339|G0000000|C0036973|C0042963|C0027497
119,"126 ||| STATISTICAL ANALYSIS ||| 2.82 ||| Subsequent to this comparison with our standard protocol, further studies focusing on OMS are warranted to more clearly determine the optimal regimen.-",N,subsequent comparison standard protocol studies focusing oms warranted determine optimal regimen -,C0332282|C1707455|C1442989|C0442711|C0947630|C0000936|C1833692|G0000000|G0000000|C2698651|C0040808|G0000000
120,"58 ||| STATISTICAL ANALYSIS ||| 2.14 ||| Although more women in the dinoprostone vaginal insert group whose Bishop score at baseline was 4 or 5 had successful induction (17 of 20, 85.0%) compared with the misoprostol group (13 of 21, 61.9%), the difference was not statistically significant (P ¼ .095).",O,women dinoprostone vaginal insert bishop score baseline 4 5 successful induction 17 20 85 0% compared misoprostol 13 21 61 9% difference statistically 095,C0043210|C0012472|C0042232|C0441587|C1551458|C0449820|C0168634|G0000000|G0000000|C0597535|C0205263|C0450371|C0450371|C0450371|G0000000|C1707455|C0085174|C0450371|C0450371|C0450371|G0000000|C1705241|C0038215|C1442061
121,17 |||  ||| 0.17 ||| Misoprostol has a short half-life (20-40 minutes) following oral administration.,I,misoprostol short half-life 20-40 minutes oral administration,C0085174|C1282927|C0018517|C0450371|C0439232|C0442027|C0001554
122,"72 ||| STATISTICAL ANALYSIS ||| 2.28 ||| The woman in the dinoprostone group underwent cesarean delivery approximately 20 hours after treatment, and the woman in the oral misoprostol group had a vaginal delivery after approximately 23 hours.",I,woman dinoprostone underwent cesarean delivery 20 hours treatment woman oral misoprostol vaginal delivery 23 hours,C0043210|C0012472|G0000000|C3841297|C0011209|C0450371|C0439227|C0039798|C0043210|C0442027|C0085174|C0042232|C0011209|C0450371|C0439227
123,103 ||| STATISTICAL ANALYSIS ||| 2.59 ||| Apgar score <7 at 1 min 7 (8.75) 10 (12.5) .442,I,apgar score <7 1 min 7 8 75 10 12 5 442,C0741195|C0449820|G0000000|G0000000|C0702093|G0000000|G0000000|C0450371|C0450371|C0450371|G0000000|C1442061
124,15 |||  ||| 0.15 ||| Randomized clinical trial between hourly titrated oral misoprostol and vaginal dinoprostone for induction of labor.,I,randomized clinical trial hourly titrated oral misoprostol vaginal dinoprostone induction labor,C0034656|C0205210|C0008976|C0558292|C1883350|C0442027|C0085174|C0042232|C0012472|C0205263|C0022864
125,"14 |||  ||| 0.14 ||| Cite this article as: Rouzi AA, Alsibiani S, Mansouri N, et al.",N,cite article rouzi aa alsibiani mansouri al,G0000000|C1706852|G0000000|C0282379|G0000000|G0000000|C0202311
126,12 |||  ||| 0.12 ||| The groups were similar for demographic and clinical factors.,N,demographic clinical factors,C0011298|C0205210|C1521761
127,"74 ||| STATISTICAL ANALYSIS ||| 2.30 ||| Proportions of neonates with an Apgar score less than 7 at 1 minute were similar between groups (P ¼ .442), and all scores were 7 or greater at 5 minutes.",I,proportions neonates apgar score 7 1 minute 442 scores 7 5 minutes,C1709707|C0021289|C0741195|C0449820|G0000000|G0000000|C0439232|C1442061|C0449820|G0000000|G0000000|C0439232
128,"20 |||  ||| 0.20 ||| Based on pharmacokinetics, previously published regimens, and the incidence of side effects, we hypothesized that stepwise hourly titrated oral misoprostol is efficacious and safe.",O,based pharmacokinetics published regimens incidence effects hypothesized stepwise hourly titrated oral misoprostol efficacious safe,C1527178|C0031327|C0034037|C2945654|C0021149|C1280500|G0000000|G0000000|C0558292|C1883350|C0442027|C0085174|C1280519|G0000000
129,"79 ||| STATISTICAL ANALYSIS ||| 2.35 ||| Although misoprostol is not approved for labor induction, its comparative cost advantage over dinoprostone combined with greater satisfaction with oral administration contributed to its widespread off-label use for this indication.",O,misoprostol approved labor induction comparative cost advantage dinoprostone combined satisfaction oral administration contributed widespread off-label indication,C0085174|C0205540|C0022864|C0205263|G0000000|C0010186|G0000000|C0012472|C0205195|C0242428|C0442027|C0001554|C1880177|C0205219|C0181496|C0392360
